

BIOCON GROUP

FACT SHEET

Jun/12

Q1 FY 2013 vs. Q1 FY 2012

**BIOCON LIMITED (CONSOLIDATED) UNAUDITED
BALANCE SHEET**

(Rs. Crores)

	June 30, 2012	March 31, 2012
EQUITY AND LIABILITIES		
Shareholder's Funds		
(a) Share capital	100	100
(b) Reserves and surplus	2,252	2,172
	2,352	2,272
Minority interest	4	4
Non-current liabilities		
(a) Long-term borrowings	83	70
(b) Deferred Tax Liability (net)	-	-
(c) Other long-term liabilities	623	583
	706	653
Current liabilities		
(a) Short-term borrowings	122	187
(b) Trade payables	326	348
(c) Other current liabilities	291	269
(d) Short-term provisions	224	212
	963	1,016
TOTAL	4,025	3,945
ASSETS		
Non-current assets		
(a) Fixed Assets	1,688	1,660
(b) Non-current investments	227	64
(c) Deferred Tax Asset (net)	15	8
(d) Long term Loans and Advances	198	190
(e) Other non-current assets	26	24
	2,154	1,945
Current assets		
(a) Current Investments	509	492
(b) Inventories	396	378
(c) Trade Receivables	511	492
(d) Cash and cash equivalents	378	523
(e) Short term loans and advances	47	85
(f) Other current assets	30	30
	1,871	2,000
TOTAL	4,025	3,945

**BIOCON LIMITED (CONSOLIDATED) UNAUDITED
PROFIT & LOSS STATEMENT**

(Rs. Crores)

Particulars	Q1 FY 13	Q4 FY 12	Variance	Q1 FY 12	Variance
INCOME					
Biopharmaceuticals	368	427	-14%	299	23%
Branded formulations - India	86	65	32%	57	52%
Total Biopharmaceuticals	454	492	-8%	356	28%
Contract research	123	118	4%	88	40%
Total Sales	577	610	-5%	444	30%
Other income	16	12	30%	20	-21%
Total Revenue	593	622	-5%	464	28%
EXPENDITURE					
Material & Power Costs	279	277	1%	212	31%
Staff costs	84	76	11%	64	31%
Research & Development	36	53	-32%	20	75%
Other Expenses	55	60	-8%	35	60%
Manufacturing, staff & other expenses	454	466	-3%	332	37%
PBDIT /EBITDA	139	156	-11%	132	5%
Interest and finance charges	3	3	7%	5	-35%
Depreciation & Amortisation	43	43	-1%	45	-5%
PBT	93	110	-16%	82	13%
Taxes	14	12	14%	12	15%
NET PROFIT FOR THE PERIOD	79	98	-19%	70	13%
Minority Interest	0	-		-	
NET PROFIT FOR THE PERIOD, AFTER MINORITY	79	98	-19%	70	12%
EPS Rs.	4.0	4.9		3.5	
<p>Note: 1.The figures are rounded off to the nearest crores, percentages are based on absolute numbers</p> <p>2. Figures of the Comparative period have been regrouped wherever necessary</p>					
Biopharmaceuticals Income includes:					
Licensing development fees	-	46		15	
Licensing Income	14	-		-	